¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå : ½ÃÀå ±Ô¸ð, ¿¹Ãø, Á¡À¯À², µ¿Çâ, ¼ºÀå±âȸ ºÐ¼® º¸°í¼­ - Á¦Ç° À¯Çüº°, °ø±Þ¿øº°, ¿ëµµº°, Ä¡·á ºÐ¾ßº°, Áö¿ªº°(2021-2031³â)
Biopharmaceutical Contract Manufacturing Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type, Source, Application, Therapeutic Area, and Geography
»óǰÄÚµå : 1761162
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 243 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,450 £Ü 6,166,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 6,450 £Ü 8,938,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,450 £Ü 11,710,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ±Ô¸ð´Â 2024³â 409¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2031³â¿¡´Â 1,010¾ï 5,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2031³â CAGR 13.8%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. »ý¹°Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ´ë, ºñ¿ëÈ¿À² ¹× À¯¿¬¼º¿¡ ´ëÇÑ ¼ö¿ä Áõ´ë´Â ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ±Ô¸ðÀÇ È®´ë¿¡ ±â¿©ÇÏ´Â ÁÖ¸ñÇÒ ¸¸ÇÑ ¿äÀÎÀÔ´Ï´Ù. ±×·¯³ª ¿¹»êÀÇ Ç̹ڰú °æÁ¦ÀÇ ºÒÈ®½Ç¼ºÀÌ ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀåÀÇ ¼ºÀåÀ» °¡·Î¸·°í ÀÖ½À´Ï´Ù.

´ÜÀÏŬ·ÐÇ×ü, À¯ÀüÀÚ Ä¡·á, ¼¼Æ÷ ±â¹Ý Ä¡·á´Â º¸´Ù Çõ½ÅÀûÀ̰í ÇÕ¸®ÀûÀÎ Á¦Á¶ °øÁ¤ÀÇ Çʿ伺À» âÃâÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú Á¦Á¶ ¼öŹ ±â°ü(CMO)Àº ¿¬¼Ó Á¦Á¶, ÀÚµ¿È­, ÀΰøÁö´É(AI), ÇÁ·Î¼¼½º ºÐ¼®±â¼ú(PAT) µî ¼±Áø ±â¼úÀ» äÅÃÇØ »ý»ê´É·ÂÀ» °­È­ÇÏ°í ¹ÙÀÌ¿ÀÀǾàǰ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÏ´Â ¿òÁ÷ÀÓÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¿¬¼Ó Á¦Á¶´Â, »ý¹° Á¦Á¦ÀÇ ¿¬¼Ó »ý»êÀ» °¡´ÉÇÏ°Ô ÇØ, Àϰü¼º, ½ºÇǵå, È¿À²À» ³ôÀÌ´Â °ÍÀ¸·ÎºÎÅÍ, ¹ÙÀÌ¿À ÀǾàǰ ¾÷°è¿¡¼­ ±Þ¼ÓÈ÷ º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ÇÁ·Î¼¼½º¸¦ ÅëÇØ Á¦Á¶ °øÁ¤ °£ÀÇ ´Ù¿îŸÀÓÀÌ ´ÜÃàµÇ°í Áß°£ ÀúÀåÀÇ Çʿ伺ÀÌ ÃÖ¼ÒÈ­µÇ¹Ç·Î Á¦Á¶ ºñ¿ëÀÌ ´ëÆø Àý°¨µË´Ï´Ù. º£ÀÌÄ¿ ¸ÅÄËÁöÀÇ º¸°í¼­¿¡ µû¸£¸é, ¿¬¼Ó Á¦Á¶´Â »ý¹° Á¦Á¦ÀÇ Á¦Á¶ ºñ¿ëÀ» 30% Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù. ³ë¹ÙƼ½º¿Í È­ÀÌÀÚ´Â ´ë±Ô¸ð »ý¹°ÇÐÀû Á¦Á¦ Á¦Á¶¿¡ ¿¬¼Ó Á¦Á¶¸¦ µµÀÔÇϰí ÀÖ´Â ´ë±â¾÷ Áß Çϳª·Î, ¾÷¹« È¿À² °³¼±°ú ºñ¿ë Àý°¨¿¡ È¿°úÀûÀÓÀ» º¸¿©ÁÝ´Ï´Ù.

ÀΰøÁö´É(AI)Àº °øÁ¤ ÃÖÀûÈ­, ¿¹Áöº¸Àü, ǰÁú°ü¸®¿¡µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. AI ±â¹Ý µµ±¸´Â ¹æ´ëÇÑ ¾çÀÇ »ý»ê µ¥ÀÌÅ͸¦ ½Ç½Ã°£À¸·Î ºÐ¼®ÇØ ÀáÀçÀûÀÎ ¹®Á¦°¡ ¹ß»ýÇϱâ Àü¿¡ ÆÄ¾ÇÇÏ°í »ý»ê ÇÁ·Î¼¼½º Àüü¸¦ ÅëÇØ ÃÖÀûÀÇ »óŸ¦ È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº CMO°¡ ´Ù¿îŸÀÓÀ» ÃÖ¼ÒÈ­ÇÏ°í ¼öÀ²À» Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÄÚ±×´ÏÀÜÆ®¿Í °°Àº ±â¾÷Àº ÀÌ¹Ì AI¸¦ »ç¿ëÇÏ¿© Á¦Á¶ ÇÁ·Î¼¼½ºÀÇ ÀáÀçÀûÀÎ ¿À·ù¸¦ ¿¹ÃøÇϰí ÀÇ»ç°áÁ¤À» °³¼±Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ÇÁ·Î¼¼½º ºÐ¼® ±â¼ú(PAT)Àº, Áß¿äÇÑ ÇÁ·Î¼¼½º ÆÄ¶ó¹ÌÅÍÀÇ ½Ç½Ã°£ ¸ð´ÏÅ͸µ°ú Á¦¾î¸¦ °¡´ÉÇÏ°Ô ÇØ, »ý¹° Á¦Á¦ÀÇ ´ë±Ô¸ð ¹èÄ¡ Àüü¿¡¼­ ÀϰüµÈ ǰÁúÀ» º¸ÁõÇÕ´Ï´Ù. PAT¸¦ ÅëÇÕÇÔÀ¸·Î½á Á¦Á¶¾÷ü´Â Á¦Á¶ °øÁ¤ÀÇ ºü¸¥ ´Ü°è¿¡¼­ ÆíÂ÷¸¦ °ËÃâÇÏ°í °áÇÔÀ̳ª ºÎÁ¤ÇÕÀ» ¹æÁöÇϱâ À§ÇØ ½Ç½Ã°£À¸·Î Á¶Á¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú Á¦Ç°ÀÇ Ç°ÁúÀÌ Çâ»óµÇ°í ¸®¼Ò½º¸¦ º¸´Ù È¿À²ÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾î ½Ã°£°ú ºñ¿ë ¸ðµÎ Àý°¨µË´Ï´Ù. µû¶ó¼­ ¿¬¼Ó Á¦Á¶, ÀÚµ¿È­, AI, PAT µî °íµµÀÇ Á¦Á¶±â¼ú äÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ÇâÈÄ ¼ö³â°£ ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ä¡·á ¿µ¿ª ±â¹Ý ÀλçÀÌÆ®

Ä¡·á ºÐ¾ß¿¡ µû¶ó ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀåÀº Á¾¾çÇÐ, ÀÚ°¡¸é¿ªÁúȯ, È£Èí±âÁúȯ, ´ë»çÁúȯ, ½Å°æÇÐ, °¨¿°Áõ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2024³â ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå Á¡À¯À²Àº ¾Ï ºÐ¾ß°¡ ÃÖ´ë¿´½À´Ï´Ù. ¾ÏÀº ¿©ÀüÈ÷ ¼¼°è »çÀÎÀÇ 1À§À̱⠶§¹®¿¡ ¼±ÁøÀûÀÎ ¾Ï Ä¡·á¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é 2022³â¿¡´Â Àü ¼¼°èÀûÀ¸·Î 2,000¸¸ ¸íÀÇ ½Å±Ô ¾Ï ȯÀÚ¿Í 970¸¸ ¸íÀÇ ¾Ï °ü·Ã »ç¸ÁÀÌ º¸°íµÇ¾ú½À´Ï´Ù. ÀÌ ¼ö¿ä´Â ÁÖ·Î »ý¹°ÇÐÀû Á¦Á¦ÀÇ °³¹ß¿¡ ÀÇÇØ ÃÊ·¡µÇ°í ÀÖÀ¸¸ç, »ý¹°ÇÐÀû Á¦Á¦ÀÇ Á¦Á¶¿¡´Â º¹ÀâÇÑ ¼¼Æ÷¹è¾ç ½Ã½ºÅÛ°ú ¾ö°ÝÇÑ Ç°Áú°ü¸® Á¶Ä¡°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ¸¹Àº Á¦¾à±â¾÷¿¡¼­ Á¦Á¶À§Å¹Ã³·ÎÀÇ ¾Æ¿ô¼Ò½ÌÀº ½ÇÇà °¡´ÉÇÑ ¼Ö·ç¼ÇÀÌ µÇ°í ÀÖ½À´Ï´Ù. ŰƮ·ç´Ù´Â 2024³â 294¾ï 8,000¸¸ ´Þ·¯ÀÇ ¸ÅÃâ¾×À» ±â·ÏÇßÀ¸¸ç, ¾Ï »ý¹°ÇÐÀû Á¦Á¦ÀÇ °Å´ëÇÑ ½ÃÀå ÀáÀç·ÂÀ» ºÎ°¢½ÃÄ×½À´Ï´Ù. ¶ÇÇÑ Æ¯È÷ Kymriah(tisagen lecleucel)³ª Yescarta(axicabtagene ciloleucel) µîÀÇ CAR-T ¿ä¹ýÀ» Áß½ÉÀ¸·Î ÇÑ °³º°È­Á¾¾ç Ä¡·á¿¡ ´ëÇÑ °æÇâÀÇ °íÁ¶µµ °íµµ·Î Àü¹®È­µÈ ¼öŹÁ¦Á¶ÀÇ Çʿ伺¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¿¡´Â À¯ÀüÀÚ Á¶ÀÛ ¸é¿ª¼¼Æ÷ÀÇ »ý»êÀÌ ÇÊ¿äÇϰí, ¼¼Æ÷ Ä¡·á³ª À¯ÀüÀÚ Ä¡·á¿¡ Á¤ÅëÇÑ CMO¿¡ ´ëÇÑ ¼ö¿ä°¡ »ý°Ü, ¹ÙÀÌ¿À ÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO), ¼¼°èÀÚ°¡¸é¿ª¿¬±¸¼Ò(Global Autoimmune Institute 2022) º¸°í¼­, ±¹Á¦´ç´¢º´¿¬ÇÕ(International Diabetes Federation) µîÀº ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå º¸°í ÀÛ¼º ½Ã ÂüÁ¶ÇÑ 1Â÷ ¹× 2Â÷ Á¤º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀåÀÇ Á¤¼¼

Á¦5Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦6Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå : ½ÃÀå ºÐ¼®

Á¦7Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ºÐ¼® : Á¦Ç° À¯Çüº°

Á¦8Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ºÐ¼® : °ø±Þ¿øº°

Á¦9Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ºÐ¼® : ¿ëµµº°

Á¦10Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå ºÐ¼® : Ä¡·á ºÐ¾ßº°

Á¦11Àå ¹ÙÀÌ¿ÀÀǾàǰ ¼öŹ Á¦Á¶ ½ÃÀå : Áö¿ªº° ºÐ¼®

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå ¾÷°è Á¤¼¼

Á¦14Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦15Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The biopharmaceutical contract manufacturing market size is expected to grow from US$ 40.99 billion in 2024 to US$ 101.05 billion by 2031; it is projected to register a CAGR of 13.8% during 2025-2031. Rising demand for biologics and increasing demand for cost efficiency and flexibility are noteworthy factors contributing to the expansion of the biopharmaceutical contract manufacturing market size. However, the tightened budget and economic uncertainty hinder the biopharmaceutical contract manufacturing market growth.

Monoclonal antibodies, gene therapies, and cell-based treatments have created the need for more innovative, streamlined manufacturing processes. As a result, contract manufacturing organizations (CMOs) are increasingly adopting advanced technologies such as continuous manufacturing, automation, artificial intelligence (AI), and process analytical technologies (PAT) to enhance production capabilities and meet the growing demand for biopharmaceuticals. Continuous manufacturing is rapidly gaining traction in the biopharmaceutical industry as it allows the uninterrupted production of biologics, providing greater consistency, speed, and efficiency. This process reduces downtime between production runs and minimizes the need for intermediate storage, significantly reducing production costs. According to a Baker McKenzie report, continuous manufacturing can reduce the cost of biologic production by 30%. Novartis and Pfizer are among the major companies implementing continuous manufacturing for large-scale biologic production, demonstrating its effectiveness in improving operational efficiency and reducing costs.

Artificial intelligence (AI) can also be used for process optimization, predictive maintenance, and quality control. AI-based tools can analyze vast amounts of production data in real-time, identifying potential issues before they arise and ensuring optimal conditions throughout the production process. This technology helps CMOs minimize downtime and improve yield rates. Companies such as Cognizant are already using AI to predict potential failures in manufacturing processes and improve decision-making. Furthermore, process analytical technologies (PAT) enable real-time monitoring and control of critical process parameters, ensuring consistent quality across large batches of biologics. By integrating PAT, manufacturers can detect variations early in the production process and adjust in real-time to prevent defects or inconsistencies. This results in higher-quality products and more efficient use of resources, reducing both time and cost. Therefore, the increasing adoption of advanced manufacturing technologies such as continuous manufacturing, automation, AI, and PAT is expected to contribute to the growth of the biopharmaceutical contract manufacturing market in the coming years.

Therapeutic Area-Based Insights

Based on the therapeutic area, the biopharmaceutical contract manufacturing market is segmented into oncology, autoimmune disorders, respiratory disorders, metabolic disorders, neurology, infectious diseases, and others. The oncology segment held the largest biopharmaceutical contract manufacturing market share in 2024. As cancer remains a leading cause of death globally, it drives the need for advanced cancer treatments. According to the World Health Organization (WHO), 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally in 2022. This demand is primarily driven by the development of biologics and the production of biologics involves complex cell culture systems and stringent quality control measures, making outsourcing to contract manufacturers a viable solution for many pharmaceutical companies. Keytruda generated US$ 29.48 billion in sales in 2024, highlighting the immense market potential of oncology biologics. Additionally, the increasing trend toward personalized oncology treatments, particularly with CAR-T therapies such as Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel), has also fueled the need for highly specialized contract manufacturing. These treatments require the production of genetically modified immune cells, which creates the demand for CMOs with expertise in cell and gene therapies, thereby fueling the biopharmaceutical contract manufacturing market growth.

World Health Organization (WHO), Global Autoimmune Institute 2022 report, and International Diabetes Federation are among the primary and secondary sources referred to while preparing the biopharmaceutical contract manufacturing market report.

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Biopharmaceutical Contract Manufacturing Market Landscape

5. Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics

6. Biopharmaceutical Contract Manufacturing Market - Global Market Analysis

7. Biopharmaceutical Contract Manufacturing Market Analysis - by Product Type

8. Biopharmaceutical Contract Manufacturing Market Analysis - by Source

9. Biopharmaceutical Contract Manufacturing Market Analysis - by Application

10. Biopharmaceutical Contract Manufacturing Market Analysis - by Therapeutic Area

11. Biopharmaceutical Contract Manufacturing Market - Geographical Analysis

12. Competitive Landscape

13. Industry Landscape

14. Company Profiles

15. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â